![]() |
市场调查报告书
商品编码
1497628
细胞治疗市场:按支架、按应用划分 - 2024-2030 年全球预测Acellular Therapy Market by Scaffold (Cell Laden Hydrogel, Extracellular Matrix (ECM), Fused Deposition Modeling (FDM)), Application (Cardiology, Gastroenterology, Hepatology) - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年细胞治疗市场规模为110.7亿美元,预计2024年将达到124.9亿美元,2030年将达到266.5亿美元,复合年增长率为13.37%。
细胞疗法代表再生医学的一个分支,利用细胞成分来修復和再生组织和器官。这些成分包括多种生物分子,如蛋白质、胜肽、生长因子、细胞外基质(ECM)成分和合成的生物活性化合物,但不包括活细胞。该治疗方法利用这些细胞材料的领导潜力来刺激身体的内部修復机制并为组织再生提供支架。 KEYWORD 市场成长受到慢性病盛行率增加、治疗技术进步以及再生医学研究投资增加等因素的影响。此外,政府积极支持再生医学的努力也正在加速细胞疗法的交付。然而,疗法开发的高成本、严格的监管要求以及製造流程的复杂性影响了细胞疗法的开发。细胞治疗市场的潜在机会包括开拓具有增强生物相容性和生物活性的生医材料、与技术公司合作开发先进製造技术以及开拓新兴国家开拓的市场。
主要市场统计 | |
---|---|
基准年[2023] | 110.7亿美元 |
预测年份 [2024] | 124.9亿美元 |
预测年份 [2030] | 266.5亿美元 |
复合年增长率(%) | 13.37% |
区域洞察
在美国,特别是美国,细胞疗法已广泛应用于多种临床应用,包括创伤治疗、整形外科治疗以及最近的整容手术。 Acela 疗法在美洲的生产非常复杂,严格的 FDA 法规确保了最高的品质和安全标准。在亚太地区,日本、韩国、中国和印度等国家正成为细胞治疗的重要市场。在这些国家,不断增长的糖尿病人口增加了这些治疗方法在慢性伤口和糖尿病溃疡治疗中的使用。此外,经济成长和医疗保健投资使亚太地区成为新兴的医疗旅游中心,直接影响细胞治疗药物等先进治疗方法的使用。中国和韩国特别投资扩大产能,而日本则以其再生医学创新而闻名。欧洲拥有成熟的细胞治疗市场,拥有用于伤口护理、组织再生和外科应用的先进产品。许多大公司已经进入这个领域并正在推动技术创新。中东和非洲部分地区也认识到了蜂窝产品的潜力,但由于广大地区的经济和医疗保健系统不同,其采用情况并不均衡。欧洲国家拥有符合 EMA 指南的强大生产框架,确保高品质生产。德国、英国、法国等生物技术中心拥有强大的生产能力。
FPNV定位矩阵
FPNV 定位矩阵对于评估供应商在细胞治疗市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对细胞治疗市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争力的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在细胞治疗市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[195 Pages Report] The Acellular Therapy Market size was estimated at USD 11.07 billion in 2023 and expected to reach USD 12.49 billion in 2024, at a CAGR 13.37% to reach USD 26.65 billion by 2030.
Acellular therapy represents a branch of regenerative medicine that utilizes acellular components with the goal of repairing or regenerating tissues and organs. These components can include various biomolecules such as proteins, peptides, growth factors, extracellular matrix (ECM) components, and synthetic bioactive compounds but lack any living cells. This form of therapy harnesses the instructive potential of these acellular materials to stimulate the body's intrinsic repair mechanisms or to provide a scaffold for tissue regeneration. The growth of the acellular therapy market is influenced by factors such as the increasing prevalence of chronic diseases, advancements in treatment technology, and growing investments in regenerative medicine research. Further, favorable government initiatives to support regenerative medicine have also accelerated the provision of acellular therapy. However, the high cost of therapy development, stringent regulatory requirements, and the complexity of the manufacturing process impact the acellular therapy development. Potential opportunities within the acellular therapy market include the development of biomaterials with enhanced biocompatibility and bioactivity, collaboration with technology companies for advanced manufacturing techniques, and exploring untapped markets in developing countries.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 11.07 billion |
Estimated Year [2024] | USD 12.49 billion |
Forecast Year [2030] | USD 26.65 billion |
CAGR (%) | 13.37% |
Regional Insights
The Americas, particularly the United States, have witnessed widespread adoption of acellular therapy across multiple clinical applications, including wound healing, orthopedic treatments, and, increasingly, cosmetic procedures. The production of acellular therapies in the Americas is highly sophisticated, with stringent FDA regulations ensuring the highest quality and safety standards. In the APAC region, countries such as Japan, South Korea, China, and India are emerging as significant markets for acellular therapy. These countries are seeing increasing use of these therapies in managing chronic wounds and diabetic ulcers due to a growing diabetic population. Further, growing economies and healthcare investments have seen the APAC become a burgeoning medical tourism hub, directly impacting the use of advanced therapies such as acellular therapeutics. China and South Korea are particularly invested in scaling up production capacity, and Japan is known for its innovation in regenerative medicine. Europe has a well-established acellular therapy market, with advanced products used in wound care, tissue regeneration, and surgical applications. The presence of a number of leading companies here drives innovation in the sector. The Middle East and parts of Africa are also recognizing the potential for acellular products; however, their adoption is varied due to differing economic and healthcare systems within the vast region. European countries have robust production frameworks governed by EMA guidelines, which ensure high-quality production. Biotechnology hubs in countries including Germany, the UK, and France have strong production capabilities.
Market Insights
The market dynamics represent an ever-changing landscape of the Acellular Therapy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Acellular Therapy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Acellular Therapy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Humacyte Announces Positive Top-Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma
Humacyte, Inc. unveiled promising results from its pivotal V005 Phase 2/3 study concerning the application of the Human Acellular Vessel (HAV) for emergency vascular trauma repair. This single-arm clinical trial demonstrated that HAV displayed a superior performance, with higher patency rates and notably fewer occurrences of amputation and infection when juxtaposed with historical data on synthetic vascular grafts. [Published On: 2023-09-12]
FDA Approves Lantidra, a Cellular Therapy for Type 1 Diabetes
The U.S. Food and Drug Administration (FDA) has greenlit Lantidra (donislecel-jujn), a pioneering cellular therapy treatment for adults with type 1 diabetes who consistently struggle to reach their target HbA1c levels due to recurrent severe hypoglycemia, despite undergoing rigorous diabetes management and education. Engineered as the first allogeneic pancreatic islet cell therapy sanctioned by the FDA, Lantidra facilitates insulin regulation through the delivery of allogeneic islet beta cells. [Published On: 2023-06-29]
Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries
Humacyte, Inc. a pioneering clinical-stage biotech firm specializing in the development of universally implantable bioengineered human tissues, has initiated a humanitarian project to distribute its revolutionary Human Acellular Vessels (HAVs) to several Ukrainian hospitals for critical vascular repair treatment in both civilians and military personnel suffering from vascular injuries. The inaugural batch of HAVs, designed as engineered, off-the-shelf vessels for a variety of vascular treatments, has embarked for Ukraine, targeting six medical facilities across cities including Kyiv and Kharkiv. [Published On: 2022-05-09]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Acellular Therapy Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Acellular Therapy Market, highlighting leading vendors and their innovative profiles. These include Allergan Inc. by Abbvie Inc., AlloSource, Aziyo Biologics, Baxter International, Becton, Dickinson and Company, BioHorizons, Inc., EnColl Corporation, Engitix Ltd, Fidia Farmaceutici S.p.A, GSK PLC, Humacyte, Inc., In2Bones Global by CONMED Corporation, Integra LifeSciences Corporation, LifeNet Health, MiMedx Group, Organicell Regenerative Medicine, Inc., Organogenesis Holdings Inc., Reprise Biomedical, Inc., Sanofi S.A., Smith & Nephew PLC, Stryker Corporation, Tissue Regenix, Vascudyne, Inc., and Zimmer Biomet.
Market Segmentation & Coverage